Study links genetic variants to poor outcomes after anti-VEGF treatment for AMD

Variants in genes connected to age-related macular degeneration were associated with poor visual outcomes after treatment with ranibizumab or bevacizumab, according to a study.The prospective study included 224 patients with neovascular AMD who underwent intravitreal injections of 0.5 mg Lucentis (ranibizumab, Genentech) or 1.25 mg Avastin (bevacizumab, Genentech).Patients underwent three monthly injections and as-needed injections for an additional 9 months; patients received an average of 6.4 injections.

Full Story →